



Ifw  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pia Norup NIELSEN

Group Art Unit: 3761

Serial No.: 10/538,832

Examiner: Not Yet Assigned

Filed: June 13, 2005

For: URINARY CATHETER DEVICE WITH A PHARMACEUTICALLY ACTIVE  
COMPOSITION

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 21, 2005

Sir:

As a means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicant(s), through the undersigned attorney, submits this Information Disclosure Statement. The patents, publications or other information submitted herewith are listed on the attached Form PTO-1449 and copies are attached, excluding U.S. patents and publications. Please note that no English language translation for German Patent No. DE 2 317 839 is readily available, however, as noted in the Denmark Office Action (copy enclosed), this document is indicative only of the "general state of the art", and thus not particularly relevant. The patents and publications listed on Form PTO-1449 were cited in the specification, an International Search Report (ISR) and a International Preliminary

W


Examination Report (IPER) in a corresponding patent application. Copies of the ISR AND IPER are enclosed. The Examiner is requested to make these references of record in the file of this application.

In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits of the above-identified application.

Accordingly, it is respectfully submitted that no fee is required by the filing of this Information Disclosure Statement.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:   
Harvey B. Jacobson, Jr.  
Registration No. 20,851

400 Seventh Street, N.W.  
Washington, DC 20004  
(202) 638-6666  
Atty. Dkt. No. P68468US1  
HBJ/gm



**JACOBSON HOLMAN PLLC**  
 400 SEVENTH STREET, N.W., Suite 600  
 WASHINGTON, D.C. 20004-2201  
 Phone: (202) 638-6666

## LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

APPLICANT: Pia Norup NIELSEN  
 SERIAL NO.: 10/538,832  
 FILING DATE: June 13, 2005

GROUP ART UNIT: 3761  
 ATTY. DOCKET NO.: P68468US1  
 TODAY'S DATE: December 21, 2005

\*\*\*\*\*

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE (If Appropriate)
	AA	3,598,127	08/10/71	Wepsic			
	AB	4,603,152	07/29/86	Laurin et al.			
	AC	4,677,143	06/30/87	Laurin et al.			
	AD	4,834,711	05/30/89	Greenfield et al.			
	AE	4,999,210	03/12/91	Solomon et al.			
	AF	6,048,332	04/11/00	Duffy et al.			
	AG	6,050,934	04/18/00	Mikhail et al.			
	AH	6,053,905	04/25/00	Daignault, Jr., et al.			

## FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							(Yes)	(No)
	AI	DE 2 317 839	10/17/74	DE				✓
	AJ	WO 89/03232	04/20/89	WIPO				
	AK	WO 91/00074	01/10/91	WIPO				
	AL	EP 0 761 243 A1	03/12/97	EP				
	AM	WO 02/24246 A1	03/28/02	WIPO				
	AN	WO 03/002178 A2	01/09/03	WIPO				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	Martan A., et al., "Ultrasound imaging of the lower urinary tract in post-menopausal women with urinary stress . . .," Ceska Gynecol, January 1999.
	AP	Henriksson, L., et al., "A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring . . .," Am J Obstet. Gynecol, Vol. 171, No. 3, pps. 624-632, 1994.
	AQ	Ahlström, K., et al., "Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone . . .," Gynecol Obstet Invest, pps. 37-43, 1990.
	AR	Heimer, G.M., "Estriol in the postmenopause," Acta Obste Gynecol Scand. Suppl., pps. 5-23, 1987.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).